really nice read .. thank you for taking the time and

New Post Public Reply Private Reply Replies (0) Message Board
4kids petemantx #47912
261
really nice read .. thank you for taking the time and effort

4kids
Quote:

Copy of a post I just made on another site:


To all posters in general who are greatly disappointed in the company and management in particular, some basic questions regarding who to blame for your disappointment:

1) Have you ever known of a company in biotech, where the odds of any drug reaching commerciality are extremely poor, having a rise in share price prior to generation of revenues or at a point of development where odds of commerciality are greatly increased due to clinical trials progress?

Sure, a couple of companies sign nice partnership deals early in development but they are few and far between and normally they give up the ship for possible future large returns to get said partnerships.

2) Then at what stage in the trials did you expect to see a nice return on your investment in IPIX?

I would say anything prior to end of phase 2 is out of the question.

3) Did mgt not let you know years ago that their plan was to partner out their indications only after all had passed Phase 2 trials so that they could maximize stockholder return as they thought the drugs in the pipeline each had massive potential and they didn't want to sell that for pennies on the dollar prior to proving their full value?

Now when will we have knowledge as to all Phase 2 results? Oh yeah, it is in 7 weeks or less.

4) Will all shareholders acknowledge that the stock has been under the shorts microscope since way prior to the Mako article and the Mako article was the attempt to drive the share price to a level that would bankrupt the company and has hampered their ability to raise monies at a rate they could have attained except for the gross attack, lies, and deception put out by the Seeking Alpha article and which also laid bare company coffers to fight said article in court?

5) Did not the inventor of Prurisol and Kevetrin pay out of his own pocket to Aruda shares because they made an administrative error at the beginning of the company that would have made clear Aruda had no right to claiming developmental rights? Did he not also cut his salary in half seeing that he no longer had massive lab duties and thus thought it unfair he keep receiving the larger salary than he though he was now due? Has the CEO, who has lent his own money to IPIX to keep it going, shown any signs of outrageous spending habits and an out-of-control lifestyle as intimated by some posts on this board?

6) Do not all stockholders know that IPIX, and thus mgt, is currently in a quiet period by law due to the ongoing negotiations with BP CDA partners and thus Leo has no option as to whether he can release any word whatsoever that would put such negotiations at risk?

I think the above questions make my point that it is not mgt who is at fault for how the company has progressed over the last few years and that those doing all the complaining either invested in a sector (biotech) that is far beyond their investing level as to being able to do proper DD and know about the myriad obstacles confronting the company to reach a stage where revenues start rolling in.

We are now 7 weeks at most from a date when we should start hearing some of the actual developments that have been going on backstage regarding IPIX and if they are going as one would hope we will start to soon see a rise in share price, perhaps a very nice rise in share price.

If you are still POd at this investment, just look in the mirror and acknowledge you are the cause for investing here and don't try to make IPIX mgt the scapegoat.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Catholic Colleges Excel in AI Readiness, Study Shows

Updated Category News Views 4

Faith and Tech: An Unexpected Alliance? Alright, here's something that'll make you sit up: Catholic college grads are not just busy sipping their morning coffee while they muse over moral philosophy—they're out there on the front lines of artificial intelligence, better prepared and more engaged than their peers from secular schools. According to the latest Holistic...

Continue Reading
Money Market Funds Surge to Record $7.98 Trillion

Updated Category News Views 3

When Money Talks Fast: Market Funds Smash Records Picture this: money market funds have surged to an eye-watering $7.98 trillion. That's a lot of zeros, folks. And it's not just the usual humdrum growth; we're talking a hefty $44.75 billion increase in just one week, thanks to a cocktail of government funds and prime fund muscle, as the Investment Company Institute (ICI)...

Continue Reading
Wise Group Investors Alert Ahead of Key Legal Deadline

Updated Category News Views 0

Sizing Up the Legal Stakes for Wise Group Alright, here's a doozy that's bound to get your attention if you've got a stake in Wise Group plc (NASDAQ: WSE). We're talking about a looming securities class action, with the deadline to get involved barreling down like a runaway freight train. Before September 29, 2026, to be exact—mark it, circle it, do whatever you have to...

Continue Reading
Connected Retail Security: Rising Risks and Fragmented Roles

Updated Category News Views 2

Cyber Threats in the Connected Retail Landscape The retail world isn't what it used to be. Walk into a store today, and you're greeted not just by products but a web of interconnected systems screaming for attention. Sure, you've got your old-school POS systems humming along, but they're just one brittle cog in a rattling machine of IoT devices, cloud platforms, and...

Continue Reading
Capricor Faces Lawsuit: Investors Should Take Note

Updated Category News Views 4

Capricor Therapeutics: A Rough Road Ahead If you've got skin in the game with Capricor Therapeutics, these latest developments might have you feeling a bit queasy. Forget the greasy diner fare today; this situation calls for some serious contemplation and maybe a bit of antacid. Over at NASDAQ:CAPR, the air is hot with allegations, stock price nosedives, and looming legal...

Continue Reading
Russo Pushes $100M Boost for Women Entrepreneurs in FL

Updated Category News Views 0

Russo's Big Bet on Women-led Ventures There's nothing quite like a political shake-up promising to dig into government pockets without slamming taxpayers. Frank Russo, tossing his hat for Florida's governorship, is betting big on women entrepreneurs with a bold move—a $100 million Women’s Entrepreneurship Initiative. No new taxes, he claims, just smart financial...

Continue Reading
Clark Pacific's Arizona Plant to Triple Output by 2027

Updated Category News Views 0

Clark Pacific's Bold Expansion You've got to admire the guts it takes to break new ground, both literally and figuratively. That's exactly what Clark Pacific is doing by launching a spanking new facility in Coolidge, Arizona. It ain't just any plant, either. We're talking about a colossal 110-acre site that'll eventually boost the company's production capacity threefold....

Continue Reading
Ed Markey's Political Future on Shaky Ground in MA

Updated Category News Views 0

Massachusetts Voters Voice Desire for Change Ever seen an old engine stutter and cough before finally quitting? That's what Ed Markey's political career is starting to feel like. A fresh poll has surfaced, casting doubt over his steady grip on his longstanding Senate seat in Massachusetts. People are yearning for fresh faces and new ideas like never before. It's as if the...

Continue Reading
University of Phoenix Boosts Networking Strategies

Updated Category News Views 1

Building Networks: A Key to Professional Growth Listen up, because everyone and their dog is gabbing about mentorship and networking these days—and for good reason. The University of Phoenix is cracking this nut open with their latest webinar, "Build the Network That Advances Your Career: Mentors, Peers & Community," happening on September 17th. They're not just...

Continue Reading
Photronics Investors Must Act by Sept. 4, 2026 Deadline

Updated Category News Views 1

Action Time for Photronics Investors There's nothing like a looming deadline to get the adrenaline pumping, especially when you're staring down the barrel of a federal securities class action. Photronics, Inc. (NASDAQ: PLAB) has found itself tangled in legal webs, with the clock ticking down to September 4, 2026. That’s the deadline for investors to move on being the...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Tapco Tape Enhances Tool Efficiency for Builders

Updated Category News Views 276

Introducing Tapco Tape: A Game-Changer for Builders Westlake Royal Building Products, a proud member of the Westlake company family (NYSE:WLK), has recently unveiled an exciting and innovative product: Tapco Tape. This new accessory is designed specifically for Tapco Tools siding and trim brakes, enhancing their functionality and simplifying the work process for builders...

Continue Reading
New Insights on Money Supply and Political Impact Ahead

Updated Category News Views 247

Understanding Current Money Supply Trends Today, we're diving into the factors impacting the financial landscape, particularly focusing on the recent surge in money supply and its implications for investors. Money Supply Reports The money supply has reached record highs, especially pronounced during recent economic events. A notable aspect is the M2 money supply, which...

Continue Reading
Growth of Tamper-Evident Packaging: Future Trends Explored

Updated Category News Views 197

Overview of the Tamper-Evident Packaging Market The tamper-evident packaging market is on a promising trajectory, with projections indicating a rise from USD 1,948.6 million in 2025 to an estimated USD 2,775.4 million by 2035. This impressive growth is anticipated to occur at a compound annual growth rate (CAGR) of 3.6%. As the industry continues to expand, its dynamics...

Continue Reading
Avalo Therapeutics' Promising Developments in Phase 2 Clinical Trial

Updated Category News Views 78

Avalo Therapeutics' Promising Developments in Phase 2 Clinical Trial Avalo Therapeutics Inc. (NASDAQ: AVTX) has captured the attention of the investment community due to its consistent advancements in the biotechnology field. Recently, Oppenheimer has decided to maintain its Outperform rating on the company, along with an ambitious price target of $35.00. This backing...

Continue Reading
B. Riley Securities Welcomes Eric Dobi to Strengthen Expertise

Updated Category News Views 301

Strong Addition to B. Riley Securities Team B. Riley Securities, Inc. (BRS) recently announced the exciting news of welcoming Eric Dobi as a Senior Managing Director in its Real Estate Investment Banking group. This strategic move reflects the firm’s commitment to enhancing its talent pool with seasoned professionals who possess extensive networks and expertise in core...

Continue Reading